Skip to main content
. 2022 Jun 30;13:880258. doi: 10.3389/fmicb.2022.880258

Figure 2.

Figure 2

Identification of potential kinase inhibitor candidates with in vitro anti-HTNV activity. (A) Immunofluorescence staining of HTNV nucleocapsid protein after the 10 protein kinase inhibitors treatment, NC, negative control, Vehicle: Vehicle-treated control, scale bar = 500 μm. (B) Inhibitory percentage of protein kinase inhibitors to virus infection based on the immunofluorescence staining. (C) The representative Western blot staining for HTNV NP protein in the negative control (NC) group, Vehicle-treated control (VC) group, and 10 μM 10 protein kinase inhibitors treatment groups. (D) The analyzed result of expression of HTNV nucleocapsid protein in the NC, VC, and 10 protein kinase inhibitors treatment groups in A549 cells post HTNV infection, *p < 0.05 vs. Vehicle, n = 3. (E) Inhibitory activity of protein kinase inhibitors to the expression of HTNV-S gene extracted from intracellular RNA, the mRNA expression level of HTNV-S gene was normalized to the respective β-actin and analyzed, *p < 0.05 vs. Vehicle, n = 3.